Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v2-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-07-21 | 2025-07-09 |
| Drug Identification Number | 02362813 | 02362813 |
| Brand name | MYLAN-AMLODIPINE/ATORVASTATIN | MYLAN-AMLODIPINE/ATORVASTATIN |
| Common or Proper name | ATORVASTATIN AMLODIPINE | ATORVASTATIN AMLODIPINE |
| Company Name | MYLAN PHARMACEUTICALS ULC | MYLAN PHARMACEUTICALS ULC |
| Ingredients | ATORVASTATIN AMLODIPINE | ATORVASTATIN AMLODIPINE |
| Strength(s) | 40MG 10MG | 40MG 10MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 1x90 BTL CA | 1x90 BTL CA |
| ATC code | C10BX | C10BX |
| ATC description | LIPID MODIFYING AGENTS, COMBINATIONS | LIPID MODIFYING AGENTS, COMBINATIONS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2025-07-09 | 2025-07-09 |
| Actual start date | 2025-07-11 | |
| Estimated end date | 2025-07-16 | 2025-07-18 |
| Actual end date | 2025-07-18 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Quality Hold | Quality Hold |
| Health Canada comments |